Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study.

Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y, Mhashilkar A, Parker K, Vukelja S, Richards D, Hood J, Coffee K, Nemunaitis J.

Mol Ther. 2005 Jan;11(1):149-59.

2.

Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer.

Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, Do KA, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Jacobson MG, Parker K, Merritt JA, Steiner MS, Logothetis CJ.

Clin Cancer Res. 2004 Apr 15;10(8):2587-93.

3.

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.

Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P, Slaton JW, Merritt JA, Grossman HB, Dinney CP.

J Clin Oncol. 2003 Jun 15;21(12):2247-53.

PMID:
12805322
4.

Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.

Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB Jr, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M.

Clin Cancer Res. 2003 Jan;9(1):93-101.

5.

Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies.

Merritt JA, Roth JA, Logothetis CJ.

Semin Oncol. 2001 Oct;28(5 Suppl 16):105-14. Review.

PMID:
11706402
6.

Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53).

Yen N, Ioannides CG, Xu K, Swisher SG, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano RJ, Fang B, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, Nguyen D, Perez-Soler R, Pisters KM, Putnam JB Jr, Schrump DS, Shin DM, Walsh GL, Roth JA.

Cancer Gene Ther. 2000 Apr;7(4):530-6.

7.

Pericranial flap correction of superior sulcus depression in the anophthalmic orbit.

Hobar PC, Burt JD, Masson JA, Merritt JA, Trawnik R.

J Craniofac Surg. 1999 Nov;10(6):487-90.

PMID:
10726501
8.

Bivariate analysis of the p53 pathway to evaluate Ad-p53 gene therapy efficacy.

Jacobberger JW, Sramkoski RM, Zhang D, Zumstein LA, Doerksen LD, Merritt JA, Wright SA, Shults KE.

Cytometry. 1999 Oct 15;38(5):201-13.

PMID:
10516606
9.

Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.

Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB Jr, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D, Waugh MK.

J Natl Cancer Inst. 1999 May 5;91(9):763-71.

PMID:
10328106
10.

Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.

Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar AK, Fossella FV, Glisson BS, Hong WK, Khurl FR, Kurie JM, Nesbitt JC, Pisters K, Putnam JB, Schrump DS, Shin DM, Walsh GL.

Semin Oncol. 1998 Jun;25(3 Suppl 8):33-7.

PMID:
9704675
11.

Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma.

Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H.

J Clin Oncol. 1998 Jun;16(6):2221-32.

PMID:
9626224
12.

Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m.

Quan WD Jr, Dean GE, Spears L, Spears CP, Groshen S, Merritt JA, Mitchell MS.

J Clin Oncol. 1997 May;15(5):2103-10.

PMID:
9164224
13.

Adult perception of emotion intensity in human infant cries: effects of infant age and cry acoustics.

Leger DW, Thompson RA, Merritt JA, Benz JJ.

Child Dev. 1996 Dec;67(6):3238-49.

PMID:
9071779
14.

Modulation of 2',5'-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administration.

Merritt JA, Ball LA, Sielaff KM, Meltzer DM, Borden EC.

J Interferon Res. 1992 May;Spec No:7-16.

PMID:
1640114
15.

Phase 1 trial of oral bropirimine in superficial bladder cancer.

Sarosdy MF, Lamm DL, Williams RD, Moon TD, Flanigan RC, Crawford ED, Wilks NE, Earhart RH, Merritt JA.

J Urol. 1992 Jan;147(1):31-3.

PMID:
1729546
16.
17.

Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon.

Spear GT, Paulnock DM, Jordan RL, Meltzer DM, Merritt JA, Borden EC.

Clin Exp Immunol. 1987 Jul;69(1):107-15.

18.

Infection control: a cooperative effort between dental office and dental laboratory.

Merritt JA.

J Mass Dent Soc. 1987 Fall;36(4):185. No abstract available.

PMID:
3482221
19.

Modulation of 2',5'-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administration.

Merritt JA, Ball LA, Sielaff KM, Meltzer DM, Borden EC.

J Interferon Res. 1986 Jun;6(3):189-98.

PMID:
3745984
20.

How to plan for buying a lab computer.

Merritt JA.

Trends Tech Contemp Dent Lab. 1986 Apr;3(3):53-4. No abstract available.

PMID:
3459229
21.

Treatment of mitomycin-associated microangiopathic hemolytic anemia with vincristine.

Grem JL, Merritt JA, Carbone PP.

Arch Intern Med. 1986 Mar;146(3):566-8.

PMID:
3954531
22.

What can dental lab software do?

Merritt JA.

Trends Tech Contemp Dent Lab. 1986 Jan-Feb;3(1):36-8. No abstract available.

PMID:
3457417
23.

Low doses of interferon alpha result in more effective clinical natural killer cell activation.

Edwards BS, Merritt JA, Fuhlbrigge RC, Borden EC.

J Clin Invest. 1985 Jun;75(6):1908-13.

24.

You have a personal computer in your laboratory now .. how do you like it?

Merritt JA.

Trends Tech Contemp Dent Lab. 1985 Apr;2(3):41-3. No abstract available.

PMID:
3858935
25.

Measurement of 2',5'-oligoadenylate synthetase in patients receiving interferon-alpha.

Merritt JA, Borden EC, Ball LA.

J Interferon Res. 1985 Winter;5(1):191-8.

PMID:
3989336
26.

2-5A synthetase activity in patients with metastatic carcinoma and its response to interferon treatment.

Merritt JA, Meltzer DM, Ball LA, Borden EC.

Prog Clin Biol Res. 1985;202:423-30.

PMID:
3832076
27.

Augmented antiproliferative effects of interferons at elevated temperatures against human bladder carcinoma cell lines.

Groveman DS, Borden EC, Merritt JA, Robins HI, Steeves R, Bryan GT.

Cancer Res. 1984 Dec;44(12 Pt 1):5517-21.

28.

Transient neurologic dysfunction following moderate-dose methotrexate for undifferentiated lymphoma.

Martino RL, Benson AB 3rd, Merritt JA, Brown JJ, Lesser JR.

Cancer. 1984 Nov 1;54(9):2003-5.

PMID:
6478434
29.

Effects of diethyldithiocarbamate, an inhibitor of interferon antiviral activity, upon human natural killer cells.

Edwards BS, Merritt JA, Jelen PA, Borden EC.

J Immunol. 1984 Jun;132(6):2868-75.

PMID:
6202764
30.

Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans.

Hawkins MJ, Borden EC, Merritt JA, Edwards BS, Ball LA, Grossbard E, Simon KJ.

J Clin Oncol. 1984 Mar;2(3):221-6.

PMID:
6321691
31.

Decreased monocyte function in patients with Hodgkin's disease.

Leb L, Merritt JA.

Cancer. 1978 May;41(5):1794-803.

PMID:
647628
32.

Monoclonal macroglobulinemia with osteolytic lesions: a case report and review of the literature.

Leb L, Grimes ET, Balogh K, Merritt JA Jr.

Cancer. 1977 Jan;39(1):227-31. Review.

PMID:
401675
33.

Cyclophosphamide-induced changes in circulating lymphocyte kinetics in chronic lymphocytic leukemia.

Coco F, Merritt JA.

Cancer. 1970 Mar;25(3):721-7. No abstract available.

PMID:
5416836
34.

Properties of a 15-cm i.d. Multipath CO(2) Laser Amplifier and Oscillator.

Dezenberg GJ, Roy EL, Merritt JA.

Appl Opt. 1970 Feb 1;9(2):516-7. doi: 10.1364/AO.9.000516. No abstract available.

PMID:
20076232
35.

Blood and organ studies of circulating lymphocytes in humans with normal leukocyte counts.

Merritt JA, Coco FV, Desforges JF.

Am J Med Sci. 1969 Oct;258(4):237-44. No abstract available.

PMID:
5823460
36.

Complications related to blood replacement.

Merritt JA.

Am J Surg. 1968 Sep;116(3):333-6. No abstract available.

PMID:
4970943
37.

Treatment of hepatic coma in cirrhosis by plasmapheresis and plasma infusion (plasma exchange).

Sabin S, Merritt JA.

Ann Intern Med. 1968 Jan;68(1):1-7. No abstract available.

PMID:
5635319
38.

The use of a multipath cell as a CO(2)-N gas laser amplifier and oscillator.

Dezenberg GJ, Merritt JA.

Appl Opt. 1967 Sep 1;6(9):1541-3. doi: 10.1364/AO.6.001541.

PMID:
20062255
39.

Effect of magnesium on reticulocyte maturation.

Merritt JA, Desforges JF.

J Lab Clin Med. 1967 Sep;70(3):452-7. No abstract available.

PMID:
6038547
40.

Management of emergencies. XII. Untoward reactions to blood transfusion.

Merritt JA, Moloney WC.

N Engl J Med. 1966 Jun 23;274(25):1426-8. No abstract available.

PMID:
5933729
41.

Spectra observed from the laser plume in normal and malignant tissue of rodents: a preliminary report.

Minton JP, Merritt JA, Dearman JR, McKnight WB.

Life Sci. 1965 Sep;4(17):1681-4. No abstract available.

PMID:
5863375
42.

METHYLENE BLUE IN THE TREATMENT OF DECABORANE TOXICITY.

MERRITT JA Jr.

Arch Environ Health. 1965 Mar;10:452-4. No abstract available.

PMID:
14247343

Supplemental Content

Loading ...
Support Center